The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of ontuxizumab, a humanized monoclonal antibody (mAb) recognizing endosialin in Japanese patients (pts) with hepatocellular carcinoma (HCC).
 
Masafumi Ikeda
Consulting or Advisory Role - NanoCarrier
Speakers' Bureau - Abbott Laboratories; Bayer; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Guerbet; Kyowa Hakko Kirin; Merck Serono; Novartis; Takeda; Yakult Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono; Novartis (I); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Takeshi Aramaki
Honoraria - Bayer; Kyowa Hakko Kirin; Medico's Hirata; Medicon; Nippon Kayaku; TERUMO; Toshiba
Speakers' Bureau - Dainippon Sumitomo Pharma; Eisai; Nippon Kayaku
 
Yoshitaka Inaba
Consulting or Advisory Role - Eisai; Taiho Pharmaceutical
Speakers' Bureau - Bayer; Daiichi Sankyo; Eisai; Taiho Pharmaceutical
 
Kenya Nakai
Employment - Eisai
Stock and Other Ownership Interests - Eisai
 
Toshihiko Doi
Honoraria - Chugai Pharma; Novartis
Consulting or Advisory Role - Amgen; Lilly; Merck Serono; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)
 
Takuji Okusaka
Honoraria - Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - AstraZeneca; Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly; Merck Serono; Nippon Boehringer Ingelheim; Novartis; OncoTherapy Science; Ono Pharmaceutical; Otsuka; Pfizer; Sceti Medical Labo; Taiho Pharmaceutical; Takeda; Yakult Honsha